MaxWell Biosystems AG

MaxWell Biosystems has been founded on September 1^st, 2016 in Basel by four BEL collaborators, Dr. Michele Fiscella, Dr. Urs Frey, Dr. Jan Müller and Dr. Marie E. Obien. 

MaxWell Biosystems AG develops and markets high-content electrophysiology platforms to accelerate drug discovery and advance the understanding of complex neuronal systems. The company has developed high-density microelectrode arrays that enable to record electrical signals of 2D and 3D cellular preparations in vitro at network, cellular, and even subcellular level. MaxWell Biosystems has been founded in Basel and is now headquartered in Zurich.

MaxWell Biosystems’ first product, MaxOne, was based on a high-density microelectrode array (HD-MEA) developed at BEL, ETH Zurich. BEL has a long track record in developing CMOS-based microelectrode systems and in using them for neuroscience research. MaxWell Biosystems entertains close collaboration with BEL to further advance the technology and related neuroscience applications.

The current flagship products, MaxOne (single-well unit, launched in 2017) and MaxTwo (multi-well unit, launched in 2019), provide high-density microelectrode array (HD-MEA) technology for applications in neuroscience research, stem cell and tissue engineering, ophthalmology, and safety pharmacology. MaxWell Biosystems caters to more than 240 laboratories in 23 countries and serves 7 of the top 10 pharma companies worldwide. By enabling detailed functional characterization of electrogenic cells, MaxWell Biosystems’ main goals include to advance scientific breakthroughs and enable efficient drug discovery.